Advertisement
Screener

Silence Therapeutics plc (SLNCF) Other Comprehensive Income (Loss), Net of Tax

2.2 / 5 stars · 20/46 Roast Me

Silence Therapeutics plc Other Comprehensive Income (Loss), Net of Tax

Silence Therapeutics plc (SLNCF) reported Other Comprehensive Income (Loss), Net of Tax of $27.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10

  • Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $27.00K, a 99.60% decline year-over-year.
  • Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$392.00K, a 110.61% decline year-over-year.
  • Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $97.00K.
  • Silence Therapeutics plc other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$1.67M, a 121.75% decline year-over-year.
  • Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2025 was $8.80M.
  • Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2024 was -$1.05M, a 233.71% decline from fiscal 2023.
  • Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2023 was $789.00K.
  • Silence Therapeutics plc other comprehensive income (loss), net of tax for fiscal 2022 was -$86.00K.
Period endOther Comprehensive Income (Loss), Net of Tax 3 monthOther Comprehensive Income (Loss), Net of Tax 6 monthOther Comprehensive Income (Loss), Net of Tax 9 monthOther Comprehensive Income (Loss), Net of Tax 12 month
2026-06-30$27.00K
10-Q · filed 2026-08-10
-$365.00K
10-Q · filed 2026-08-10
-$268.00K
derived: sum of 3 quarters · filed 2026-08-10
-$1.94M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31-$392.00K
10-Q · filed 2026-05-07
-$295.00K
derived: sum of 2 quarters · filed 2026-05-07
-$1.96M
derived: sum of 3 quarters · filed 2026-05-07
$4.72M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$97.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$1.57M
derived: sum of 2 quarters · filed 2026-03-05
$5.11M
derived: sum of 3 quarters · filed 2026-08-10
$8.80M
10-K · filed 2026-03-05
2025-09-30-$1.67M
10-Q · filed 2025-11-06
$5.01M
derived: sum of 2 quarters · filed 2026-08-10
$8.71M
10-Q · filed 2025-11-06
-$152.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$6.68M
10-Q · filed 2026-08-10
$10.38M
10-Q · filed 2026-08-10
$1.52M
derived: sum of 3 quarters · filed 2026-08-10
$9.19M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$3.70M
10-Q · filed 2026-05-07
-$5.16M
derived: sum of 2 quarters · filed 2026-05-07
$2.51M
derived: sum of 3 quarters · filed 2026-05-07
$2.70M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$8.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$1.19M
derived: sum of 2 quarters · filed 2026-03-05
-$999.00K
derived: sum of 3 quarters · filed 2026-03-05
-$1.05M
10-K · filed 2026-03-05
2024-09-30$7.67M
10-Q · filed 2025-11-06
$7.86M
derived: sum of 2 quarters · filed 2025-11-06
$7.80M
10-Q · filed 2025-11-06
2024-06-30$186.00K
10-Q · filed 2025-08-07
$129.00K
10-Q · filed 2025-08-07
2024-03-31-$57.00K
10-Q · filed 2025-05-08
2023-12-31$789.00K
10-K · filed 2025-02-27
2022-12-31-$86.00K
10-K · filed 2025-02-27